Investors Purchase High Volume of Call Options on BioNTech (NASDAQ:BNTX)

BioNTech SE (NASDAQ:BNTXGet Free Report) was the recipient of some unusual options trading activity on Tuesday. Stock traders purchased 3,757 call options on the stock. This represents an increase of 74% compared to the average daily volume of 2,154 call options.

Wall Street Analysts Forecast Growth

BNTX has been the subject of a number of recent analyst reports. HC Wainwright reissued a “buy” rating and issued a $113.00 target price on shares of BioNTech in a research report on Wednesday, June 26th. JPMorgan Chase & Co. decreased their target price on BioNTech from $99.00 to $90.00 and set an “underweight” rating on the stock in a report on Friday, March 22nd. BMO Capital Markets cut their price target on BioNTech from $123.00 to $122.00 and set an “outperform” rating for the company in a report on Tuesday, May 7th. Evercore ISI started coverage on BioNTech in a research report on Tuesday, May 14th. They set an “inline” rating and a $100.00 price objective on the stock. Finally, UBS Group reduced their target price on shares of BioNTech from $110.00 to $101.00 and set a “neutral” rating for the company in a report on Wednesday, March 27th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and three have issued a buy rating to the company’s stock. According to MarketBeat.com, BioNTech presently has a consensus rating of “Hold” and an average target price of $111.70.

View Our Latest Analysis on BioNTech

Institutional Investors Weigh In On BioNTech

Hedge funds and other institutional investors have recently made changes to their positions in the company. Baillie Gifford & Co. grew its stake in shares of BioNTech by 1.0% during the fourth quarter. Baillie Gifford & Co. now owns 8,689,182 shares of the company’s stock valued at $917,056,000 after buying an additional 86,343 shares during the last quarter. Primecap Management Co. CA lifted its position in shares of BioNTech by 2.8% during the fourth quarter. Primecap Management Co. CA now owns 4,763,453 shares of the company’s stock worth $502,735,000 after purchasing an additional 131,490 shares during the last quarter. Harding Loevner LP purchased a new stake in shares of BioNTech during the fourth quarter valued at $410,984,000. Flossbach Von Storch AG grew its holdings in shares of BioNTech by 1.0% in the fourth quarter. Flossbach Von Storch AG now owns 3,548,660 shares of the company’s stock worth $374,526,000 after purchasing an additional 35,445 shares during the last quarter. Finally, Capital World Investors increased its stake in BioNTech by 0.5% in the 1st quarter. Capital World Investors now owns 943,116 shares of the company’s stock worth $87,002,000 after buying an additional 4,369 shares during the period. Hedge funds and other institutional investors own 15.52% of the company’s stock.

BioNTech Trading Up 0.0 %

Shares of BNTX opened at $80.51 on Wednesday. BioNTech has a fifty-two week low of $78.02 and a fifty-two week high of $125.83. The company has a debt-to-equity ratio of 0.01, a quick ratio of 11.16 and a current ratio of 11.38. The company’s fifty day moving average is $91.08 and its 200 day moving average is $93.46. The stock has a market capitalization of $19.14 billion, a PE ratio of 161.02 and a beta of 0.23.

BioNTech (NASDAQ:BNTXGet Free Report) last released its quarterly earnings results on Monday, May 6th. The company reported ($1.42) EPS for the quarter, missing the consensus estimate of ($0.82) by ($0.60). The company had revenue of $203.69 million during the quarter, compared to analysts’ expectations of $589.96 million. BioNTech had a return on equity of 0.55% and a net margin of 4.01%. Sell-side analysts expect that BioNTech will post -2 earnings per share for the current fiscal year.

About BioNTech

(Get Free Report)

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.

Further Reading

Receive News & Ratings for BioNTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioNTech and related companies with MarketBeat.com's FREE daily email newsletter.